Sign In
Section Navigation
Common TitlePREDICT-1
Official Title A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*5701) for Susceptibility to Abacavir Hypersensitivity
Phase Phase IIIA
ClinicalTrials.gov NCT00340080
Categories PharmacologyTreatment-NaiveTreatment-ExperiencedAdverse Effects
Funding
IndustryGlaxoSmithKline
References
  • Mallal S, Phillips E, Carosi G, et al; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-79.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.